BridgeBio Pharma, Inc. — Director's Dealing 2020

Jun 6, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-06-03

Reporting Person: STEPHENSON BRIAN C (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-03	Common Stock	S	1600	$30.0449	Disposed	307116	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-03	Stock Option (Right to Buy)	$28.86	A	196850	Acquired	2030-06-02	Common Stock (196850)	Direct
2020-06-03	Restricted Stock Units	$	A	27356	Acquired		Common Stock (27356)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019.

F2: Represents the weighted average sale price of the shares sold from $30.00 to $30.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The Option will vest over approximately four years. 1/48th of the shares of Common Stock underlying the Option will vest on a monthly basis after June 3, 2020 (the "Vesting Commencement Date"), such that all of the shares underlying the Option will be vested on the date four (4) years after the Vesting Commencement Date, subject to the Reporting Person's continued Service Relationship (as defined in the Plan) with the Issuer or any of its subsidiaries through the applicable vesting date.

F4: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F5: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020 and have no expiration date. In general, 6.25% of the RSUs will vest on August 16, 2020 and 6.25% will vest in quarterly installments on the 16th day of February, May, August and November, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through the applicable vesting date.